Prescriber's Corner
Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
Jessica Davis,(1) PharmD, BCOP, CPP, and Megan Wayman,(2) PharmD
From (1)Levine Cancer Institute, Charlotte, North Carolina; (2)Carolinas Medical Center, Charlotte, North Carolina
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Jessica Davis, PharmD, BCOP, CPP, 1021 Morehead Medical Drive, Charlotte, NC 28204. E-mail: jessica.m.davis@atriumhealth.org
J Adv Pract Oncol 2022;13(4):450–455 |
https://doi.org/10.6004/jadpro.2022.13.4.7 |
© 2022 Harborside™
ABSTRACT
The treatment landscape for metastatic melanoma has changed dramatically over the past few years as new medications have been developed. Encorafenib, a B-Raf protein kinase inhibitor, and binimetinib, a MEK inhibitor, were approved by the U.S. Food and Drug Administration in 2018 for the treatment of patients with unresectable or metastatic melanoma which harbor a BRAF V600E or V600K mutation. These approvals were based on findings from the COLUMBUS trial, which demonstrated improvement in progression-free survival and overall survival with the combination of encorafenib plus binimetinib compared with vemurafenib alone. Encorafenib plus binimetinib is the third BRAF plus MEK inhibitor combination to be approved, and there are clinical and practical differences between the combination regimens that should be considered when selecting an appropriate treatment regimen for patients.
For access to the full length article, please
sign in.
